Induced protein degradation for therapeutics: past, present, and future
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The concept of induced protein degradation by small molecules has emerged as a promising therapeutic strategy that is particularly effective in targeting proteins previously considered "undruggable." Thalidomide analogs, employed in the treatment of multiple myeloma, stand as prime examples. These compounds serve as molecular glues, redirecting the CRBN E3 ubiquitin ligase to degrade myeloma-dependency factors, IKZF1 and IKZF3. The clinical success of thalidomide analogs demonstrates the therapeutic potential of induced protein degradation. Beyond molecular glue degraders, several additional modalities to trigger protein degradation have been developed and are currently under clinical evaluation. These include heterobifunctional degraders, polymerization-induced degradation, ligand-dependent degradation of nuclear hormone receptors, disruption of protein interactions, and various other strategies. In this Review, we will provide a concise overview of various degradation modalities, their clinical applications, and potential future directions in the field of protein degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 2×
“Conceptually, heterobifunctional degraders contain two chemical entities, one that binds target protein and another that binds an E3 ligase, as initially described in a patent filed in 1999 (76), followed by a publication in 2001 (16).”
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 2×
“…devastating consequences of thalidomide use during pregnancy in the 1950s that resulted in teratogenicity (5), thalidomide and its close analogs, lenalidomide and pomalido-mide, were developed and approved for the treatment of multiple myeloma (6, 7) and del(5q) myelodysplastic syndrome (MDS) (8).”
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Self-citationPhthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · cited 2×
“Many heterobifunctional degraders targeting disease-relevant proteins have been developed, and a first wave of such molecules has entered clinical trials (18–21).”
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“The plant growth hormone auxin is a naturally occurring molecule that induces proximity between the SCF TIR1 ubiquitin ligase and Aux/IAA transcriptional repressors, leading to their degradation (13).”
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611 · cited 4×
“Retinoids, including ATRA, are a mainstay treatment for APL, inducing degradation of the fusion protein, PML-RARA (104).”
InfluentialThe Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · cited 1×
“…mechanistic basis for the therapeutic window of lenalidomide in del(5q) MDS. Notably, lenalidomide treatment has resulted in complete cytogenetic remission in approximately 50% of patients with MDS and achieving transfusion independence in around 70% of patients with del(5q) MDS patients (33, 34).”
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199 · cited 1×
“Recently, several induced proximity-driven approaches have been reported, such as deubiquitinase-targeting chimeras (135), lysosome-targeting chimeras (136), phosphorylation-inducing small molecules (137), tricomplex inhibitors of KRas (138), and more (139).”
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 1×
“Dimethyl fumarate is a notable example that is currently employed in clinical practice to treat relapsing-remitting multiple sclerosis (134).”
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“However, inhibiting BCL-X L results in on-target thrombocytopenia, which limits the clinical development of BCL-X L inhibitors (90–92).”
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · cited 1×
“To address such a challenge, heterobifunctional degraders, also known as proteolysis targeting chimeras (PROTACs) (16, 17), were developed.”
Thalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Self-citationAnticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · cited 1×
“Significant advances were made in 2015 with the development of high-affinity ligands for E3 ligase, such as CRBN-or VHL-based heterobifunction-al degraders (18–20).”
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537 · cited 2×
“To explore potential neosub-strates among zinc finger-containing proteins, a comprehensive genetic approach was performed to define the human zinc finger “degrome” (40).”
BackgroundMethodSelf-citationGlucocorticoid receptor control of transcription: precision and plasticity via allostery
Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.152 · Cited by 533 · cited 1×
“Nuclear hormone receptors (NHRs) constitute a family of ligand-regulated transcription factors that play a crucial role in regulating a spectrum of biological processes ranging from embryonic development to cellular differentiation, reproduction, immunity, and metabolism (101–103).”
Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509 · cited 1×
“To investigate this hypothesis, a quantitative mass spectrometry approach was employed, utilizing human embryonic stem cells as a model system (35).”
MethodSelf-citationA Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
Self-citationThe CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433 · cited 5×
“Structural studies revealed that the CDK inhibitor CR8 binds the active site of CDK12 and bridges the CDK12-DDB1 interface (68, 71).”
BackgroundInfluentialSelf-citationKinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431 · cited 1×
“Despite links to various indications, such as arthritis, atherosclerosis, systemic lupus erythematosus, psoriasis, and more (87), the inhibition of IRAK4 kinase activity has shown limited efficacy (88).”
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396
Wallace, A. D., & Cidlowski, J. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106033200 · Cited by 394 · cited 1×
“In response to ligands, NHRs alter transcriptional programs and, in many cases, are subsequently degraded via the ubiquitin-proteasome system (104), including thyroid hormone receptor (105), progesterone receptor (106), ER (107), glucocorticoid receptor (GR) (108), and PPAR γ (109).”
Rational discovery of molecular glue degraders via scalable chemical profiling
Mayor-Ruiz, C., Bauer, S., Brand, M., Kozicka, Z., Siklos, M., Imrichova, H., Kaltheuner, I. H., Hahn, E., Seiler, K., Koren, A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0594-x · Cited by 369
Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351
Deubiquitinase-targeting chimeras for targeted protein stabilization
Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338 · cited 1×
“SALL4 is an embryonic transcription factor known to play a crucial role in the development of fetal limbs during embryogenesis and is genetically associated with embryopathies (36).”
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338 · cited 1×
“The degradation of RBM39 by indisulam results in considerable splicing defects, making hematopoietic and lymphoid cell lines particularly susceptible to indisulam treatment (65).”
Mechanisms of hypoxia signalling: new implications for nephrology
Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309 · cited 1×
“This, in turn, stimulates erythropoietin synthesis and provides a therapeutic opportunity in certain forms of anemia (131).”
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood · doi:10.1182/blood.2020008676 · Cited by 229
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222 · cited 2×
“Biologically, degraders remove all activity of a protein, including scaffolding function, while enzyme inhibitors remove activity of the protein while the protein remains intact (26).”
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218 · cited 2×
“Further biochemical and structural analyses revealed that relatively weak affinity of indisulam to DCAF15 is still capable of inducing the formation of a DCAF15-indisulam-RBM39 complex through extensive protein-protein interfaces (62–64), which leads to highly selective RBM39 degradation.”
Self-citationDiscovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Self-citationChemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207
Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170 · cited 1×
“The study also demonstrated that subtle modification to the solvent-exposed moiety of a kinase inhibitor can confer molecular glue activity by engaging another E3 ligase to the target protein (74).”
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
Bonazzi, S., d’Hennezel, E., Beckwith, R. E. J., Xu, L., Fazal, A., Magracheva, A., Ramesh, R., Cernijenko, A., Antonakos, B., Bhang, H.-E. C., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.02.005 · Cited by 167
Hansen, J. D., Correa, M., Alexander, M., Nagy, M., Huang, D., Sapienza, J., Lu, G., LeBrun, L. A., Cathers, B. E., Zhang, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01489 · Cited by 159 · cited 1×
“CRBN modulators such as eragidomide (CC-90009) effectively recruit and degrade GSPT1, which functions as a translation termination factor (43, 44).”
Discovery and resistance mechanism of a selective CDK12 degrader
Jiang, B., Gao, Y., Che, J., Lu, W., Kaltheuner, I. H., Dries, R., Kalocsay, M., Berberich, M. J., Jiang, J., You, I., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00765-y · Cited by 150 · cited 1×
“Ub, ubiquitin. mechanism through which cells might evade the target degradation (58).”
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Hanzl, A., Casement, R., Imrichova, H., Hughes, S. J., Barone, E., Testa, A., Bauer, S., Wright, J., Brand, M., Ciulli, A., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01177-2 · Cited by 133
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Self-citationAcute pharmacological degradation of Helios destabilizes regulatory T cells
Wang, E. S., Verano, A. L., Nowak, R. P., Yuan, J. C., Donovan, K. A., Eleuteri, N. A., Yue, H., Ngo, K. H., Lizotte, P. H., Gokhale, P. C., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00802-w · Cited by 124
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124
Self-citationDesign principles for cyclin K molecular glue degraders
Kozicka, Z., Suchyta, D. J., Focht, V., Kempf, G., Petzold, G., Jentzsch, M., Zou, C., Di Genua, C., Donovan, K. A., Coomar, S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01409-z · Cited by 113 · cited 1×
“Structural studies revealed that the CDK inhibitor CR8 binds the active site of CDK12 and bridges the CDK12-DDB1 interface (68, 71).”
Self-citationThe application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76 · cited 2×
“…devastating consequences of thalidomide use during pregnancy in the 1950s that resulted in teratogenicity (5), thalidomide and its close analogs, lenalidomide and pomalido-mide, were developed and approved for the treatment of multiple myeloma (6, 7) and del(5q) myelodysplastic syndrome (MDS) (8).”
Mato, A. R., Wierda, W. G., Ai, W. Z., Flinn, I. W., Tees, M., Patel, M. R., Patel, K., O'Brien, S., Bond, D. A., Roeker, L. E., et al. (2022) · Blood · doi:10.1182/blood-2022-164772 · Cited by 74
Warren, M., Wang, W., Spiden, S., Chen‐Murchie, D., Tannahill, D., Steel, K. P., & Bradley, A. (2007) · genesis · doi:10.1002/dvg.20264 · Cited by 69
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability
Tsai, J. M., Aguirre, J. D., Li, Y.-D., Brown, J., Focht, V., Kater, L., Kempf, G., Sandoval, B., Schmitt, S., Rutter, J. C., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.028 · Cited by 68
Self-citationHuang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62
Thakurta, A., Gandhi, A. K., Waldman, M. F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S. A., et al. (2014) · Leukemia · doi:10.1038/leu.2013.315 · Cited by 56
Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0497-9 · Cited by 42
Cited by
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52871-9 · Cited by 47
Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry
Annunziato, S., Quan, C., Donckele, E. J., Lamberto, I., Bunker, R. D., Zlotosch, M., Schwander, L., Murthy, A., Wiedmer, L., Staehly, C., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01738-8 · Cited by 9
“The mode of action of clinically approved MGDs, such as lenalidomide, does not depend on conventional druggable pockets on the neo substrate protein itself, which provides opportunities to unlock therapeutic targets previously deemed undruggable 2 .”
Metadata
- Authors
- Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2024-01-02
- Volume
- 134
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4390508253
- Cited by
- 67
- References
- 62
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.